In the last trading session, 1.26 million shares of the Phathom Pharmaceuticals Inc (NASDAQ:PHAT) were traded, and its beta was 0.29. Most recently the company’s share price was $4.88, and it changed around $0.77 or 18.73% from the last close, which brings the market valuation of the company to $339.84M. PHAT currently trades at a discount to its 52-week high of $19.71, offering almost -303.89% off that amount. The share price’s 52-week low was $3.81, which indicates that the current value has risen by an impressive 21.93% since then. We note from Phathom Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.5 million shares, with the 3-month average coming to 1.21 million.
Phathom Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended PHAT as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Phathom Pharmaceuticals Inc is expected to report earnings per share of -1.06 for the current quarter.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Instantly PHAT has showed a green trend with a performance of 18.73% at the end of last trading. The rise to weekly highs of 5.12 on recent trading dayincreased the stock’s daily price by 4.69%. On the other hand, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is 15.64% up in the 30-day period. We can see from the shorts that 12.91 million shares have been sold at a short interest cover period of 9.48 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 72.89% from its current value. Analyst projections state that PHAT is forecast to be at a low of $18 and a high of $18.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
The year-over-year growth rate is expected to be 196.35%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 27.91M in revenue for the current quarter. 8 analysts expect Phathom Pharmaceuticals Inc to make 37.2M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.91M and 7.32M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 1,359.83%. Forecasts for the next quarter put sales growth at 407.88%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 12.50%.
PHAT Dividends
Phathom Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Mar-05.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.80% of Phathom Pharmaceuticals Inc shares, and 96.99% of them are in the hands of institutional investors. The stock currently has a share float of 100.83%. Phathom Pharmaceuticals Inc stock is held by 205.0 institutions, with FRAZIER LIFE SCIENCES MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 17.2637% of the shares, which is about 10.11 million shares worth $104.13 million.
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, with 12.7473% or 7.46 million shares worth $76.89 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
AIM Intl Mutual Fd.s -Invesco Global Fd. and Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 1.98 shares worth $9.64 million, making up 2.84% of all outstanding shares. On the other hand, Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund held roughly 1.78 shares worth around $8.69 million, which represents about 2.56% of the total shares outstanding.
